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Background: Bone loss leading to aseptic loosening of the prosthesis and periprosthetic fracture is a mode of failure in
cementless total hip arthroplasty (THA). The aim of this meta-analysis was to evaluate the effect of bisphosphonates in
preventing femoral periprosthetic bone resorption following primary cementless THA zone by zone.
Method: Clinical randomized controlled trials concerning bisphosphonates application after primary cementless
THA published up to October 2014 were retrieved from PubMed, Cochrane library, and Embase databases. The
methodological quality of the included studies was assessed by the Physiotherapy Evidence Database (PEDro)
scale. Data analysis was performed using StataSE12.0.
Results: Ten randomized controlled trials involving a total of 502 patients were assessed; the bisphosphonates
group included 256 patients and the control group included 246 patients. The meta-analysis showed that the
bone mineral density (BMD) of most femoral periprosthetic zones in bisphosphonates group was significantly
higher than that in the control group at 3 months postoperatively except zone 5 with no significant difference.
At 6 and 12 months, the BMD of bisphosphonates group was much higher than that in control group except
zone 5, which showed no statistical difference. The BMD of bisphosphonates group was persistently higher than
control group in zone 6 and 7 at 5 years postoperatively, while the other zones had no significant difference. Both
serum bone alkaline phosphatase and urinary type I collagen N-telopeptide were significantly suppressed by
bisphosphonates at 3, 6, and 12 months.
Conclusion: Bisphosphonates seem to decrease early femoral periprosthetic bone resorption after primary
cementless THA. Drug efficacy was found to be long-standing in the main load-bearing zones.
Keywords: Total hip arthroplasty, Bisphosphonate, Bone mineral density, Meta-analysisBackground
Total hip arthroplasty (THA) is an effective treatment
for end-stage avascular necrosis of femoral head, osteo-
arthritis, and rheumatoid arthritis of the hip [1]. By
2030, the demand for primary THA is estimated to
reach 572,000, and the demand for hip revision is esti-
mated to double in the USA [2]. Some studies indicated
that more than 75 % of the revision arthroplasties were
performed for aseptic loosening of the prosthesis and
periprosthetic fracture, which were all found to be the
sequel to severe periprosthetic bone loss [3].* Correspondence: lbchen@whu.edu.cn
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unless otherwise stated.Bisphosphonates are effective antiresorptive agents
which have been used successfully to treat diseases char-
acterized by osteoclast-mediated bone resorption, such
as osteoporosis, Paget disease, and metastatic bone dis-
eases [4]. Recently, several randomized controlled trials
(RCTs) were performed to investigate the effect of
bisphosphonates on femoral periprosthetic bone resorp-
tion following primary THA, most of which confirmed
its efficacy, while some doubted it [5-7]. Two systematic
reviews [8, 9] suggested that bisphosphonates have a
beneficial effect on preserving periprosthetic bone in a
short term after joint arthroplasty, while they had some
limitations: (1) They ignored the fundamental difference
between cement and cementless arthroplasty and didhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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included patients who underwent hemiarthroplasty and
total knee arthroplasty and (2) They did not describe the
periprosthetic bone loss zone by zone as they overlooked
the uneven effect of bisphosphonates induced on differ-
ent load-bearing areas of periprosthetic bone.
Therefore, we divided the femoral periprosthetic bone
stock into seven regions of interest (ROI) as described
by Gruen [10] (Fig. 1). We extracted the data of bone
mineral density (BMD) from each included RCT, studying
the effects of bisphosphonates in preventing femoral peri-
prosthetic bone resorption following primary cementless
THA. Serum bone alkaline phosphatase (BAP) and urin-
ary type I collagen N-telopeptide breakdown products
(NTX) were added as indices for the resorption. We per-
formed the meta-analysis to clarify the effect of bispho-
sphonates in the treatment of periprosthetic bone
resorption after cementless THA.
Methods
Search strategy
The PubMed, Embase, and Cochrane Central Register of
Controlled Trials were searched from their earliest entries
through October 2014. The search strategy was ((((ran-
dom*[Title/Abstract]) OR “Randomized Controlled Trial”
[Publication Type])) AND (((((hip arthroplasty [Title/Fig. 1 The seven regions of interest based on Gruen zones [10]Abstract]) OR hip replacement[Title/Abstract]) OR hip
prosthesis[Title/Abstract])) OR “Arthroplasty, Replacement,
Hip”[Mesh])) AND ((((((((risedronate[Title/Abstract]) OR
tiludronate[Title/Abstract]) OR alendronate[Title/Abstract])
OR pamidronate[Title/Abstract]) OR etidronate[Title/Ab-
stract]) OR zoledronate[Title/Abstract]) OR clodronate[-
Title/Abstract]) OR Bisphosphonate[Title/Abstract]). The
reference list of the relevant literatures was also reviewed
manually for any further relevant studies. Languages were
not restricted in this search.
Inclusion criteria and exclusion criteria
Inclusion criteria were as follows: (1) the target population
consisted of patients undergoing primary cementless
THA; (2) in the interventional group, the administration
of the bisphosphonate group was oral, intramuscular, or
intravenous, while the control group had been treated
with calcium, alfacalcidol, or no medication; (3) the out-
comes were analyzed with respect to BMD, serum BAP,
and urinary NTX; and (4) the methodological criterion
was prospective RCT.
Exclusion criteria were (1) cemented THA or other
arthroplasties and (2) animal studies.
Data extraction and assessment of methodological
quality
After the consecutive procedures of screening of titles
and abstracts, obtaining the full text of each article, and
reviewing them, articles that met the eligibility criteria
and did not meet the exclusion criteria were selected to
be included. Data were extracted and collated independ-
ently by two authors (XYZ and DCH), including author,
published year, sample size, patient age, sex, follow-up
time, intervention protocol, BMD of each ROI in fem-
oral periprosthetic bone, serum BAP, and urinary NTX.
The data of a published updated study involving the
same cohort of patients was extracted synthetically. The
original investigators were contacted when requisite data
were lacking in the publications. The methodological
quality of each included RCT was assessed by two ob-
servers independently by the Physiotherapy Evidence
Database (PEDro) scale [11], and trials with a score of 6
or more were considered high quality. Disagreements
were resolved by means of discussion with the corre-
sponding author (LBC).
Statistical methods
The meta-analysis was conducted with StataSE12.0
software. The weighted mean difference (WMD) and
95 % confidence interval (CI) were calculated for con-
tinuous data, and the relative risk (RR) and 95 % CI
were calculated for dichotomous data. The statistical
heterogeneity was tested with the chi-square test and
I2. If heterogeneity was low (P > 0.1, I2 < 50 %), a fixed-
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(P < 0.1 ,I2 > 50 %), sensitivity analysis, subgroup ana-
lyses, and meta-regression were conducted to find the
source of the heterogeneity. If the heterogeneity could
not be eliminated, a random-effect model would be
used when the result of meta-analysis had clinical
homogeneity, or descriptive analysis would be used.
Results
Study characteristics
A total of 96 potential articles were identified and
screened for the meta-analysis. After screening of titles
and abstracts, obtaining the full text of each article, and
reviewing them, ten RCTs were selected for this meta-
analysis [7, 12-20] (Fig. 2). The cumulative sample size
of 502 primary cementless THA comprised 256 with
bisphosphonates and 246 without bisphosphonates.
The main characteristics of the included studies were
summarized in Table 1 and the literature-exclusion
procedure was depicted in Fig. 2. The methodological
quality of the included RCTs was assessed with the PE-
Dro scale (Table 2), the results showed that all RCTs
were of high quality.Fig. 2 Flow chart summarizing the selection process of randomized controMean percentage changes of BMD in femoral
periprosthetic ROI
The BMD was assessed by the method of dual-energy X-
ray absorptiometry in all the included RCTs. The
changes of BMD in femoral periprosthetic ROI at
3 months after surgery were reported in four [12, 13, 16,
17] of the ten studies. The results of meta-analysis of
some ROI appeared heterogeneous, and sensitivity ana-
lysis indicated that the heterogeneity came from the
studies of Skoldenberg et al. [13] and Trevisan et al.
[17]. Subgroup analyses failed to eliminate the hetero-
geneity, then we found that, regardless of the exclusion
or inclusion of these two studies, the results of meta-
analysis were all the same and had clinical agreement, so
we included these two studies and conducted the meta-
analysis by random-effect model for the reason that
these two studies were of high quality. Meta-analysis in-
dicated that BMD ratios in the bisphosphonates group were
significantly higher than those in the control group mainly
in zones 1, 2, 3, 4, 6, and 7 (P < 0.05), while lower in zone 5
(WMD= −0.619, 95 % CI: −1.120 ~ −0.119, P < 0.015,
Table 3).
The changes of BMD in femoral periprosthetic ROI at
6 months after surgery were reported in eight [7, 12-17,l trials













Hennigs T 2002 12 66 51.5 29/27 42/24 Subgroup 1: oral alendronate 10 mg/day for 10 weeks
Subgroup 2: oral alendronate 20 mg/day for 5 weeks
Arabmotlagh M 2006 72 51 62.5 26/25 27/24 Subgroup 1: oral alendronate 20 mg/day for 2 months,
thereafter 20 mg/day for 4 months
Subgroup 2: oral alendronate 20 mg/day for 2 months,
thereafter 20 mg/day for 6 months
Arabmotlagh M 2009 72 49 62.5 25/24 29/20 Subgroup 1: oral alendronate 10 mg/day for 10 weeks
Subgroup 2: oral alendronate 20 mg/day for 5 weeks
Iwamoto N 2011 12 60 65 14/46 20/40 Oral alendronate 5 mg/day for 48 weeks
Skoldenberg OG 2011 24 73 60 30/43 36/37 Oral risedronate 35 mg/week for 6 months
Tapaninen TS 2010 60 16 61.4 7/9 7/9 Oral alendronate 10 mg/day for 6 months
Trevisan C 2010 12 91 64.7 53/58 42/49 Oral clodronate 100 mg/day for 10 days, thereafter
100 mg/week for 50 weeks
Venesmaa PK 2001 6 13 62.62 6/7 8/5 Oral alendronate 10 mg/day for 6 months
Yamaguchi K 2005 12 43 68.5 0/44 26/17 Subgroup 1: oral etidronate 200 mg/day for 2 weeks,
followed by 12 weeks of calcium lactate of
500 mg/day, the cycle was repeated four times
Subgroup 2: oral etidronate 400 mg/day for 2 weeks,
followed by 12 weeks of calcium lactate of
500 mg/day, the cycle was repeated four times
Yamasaki S 2007 6 40 66.7 4/36 19/21 Oral risedronate 2.5 mg/week for 6 months
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through the same method, and random-effect model
would be used if necessary. The pooling result showed
that the BMD of the bisphosphonates group in most
zones were significantly higher than that of the control
group (P < 0.05, Table 4) except no statistical difference ofTable 2 PEDro critical appraisal scores
Author PEDro critical appraisal score Total
1 2 3 4 5 6 7 8 9 10 11
Hennigs T 2002 Y Y Y Y Y Y N Y Y Y Y 9
Arabmotlagh M 2006 Y Y Y Y Y Y N Y Y Y Y 9
Arabmotlagh M 2009 Y Y Y Y Y Y N Y Y Y Y 9
Iwamoto N 2011 Y Y Y Y Y N N Y Y Y Y 8
Skoldenberg OG 2011 Y Y Y Y Y Y N Y Y Y Y 9
Tapaninen TS 2010 Y Y N Y N N N Y Y Y Y 6
Trevisan C 2010 Y Y N Y N N N Y Y Y Y 6
Venesmaa PK 2001 Y Y Y Y N N N Y Y Y Y 7
Yamaguchi K 2005 Y Y N Y N N N Y Y Y Y 6
Yamasaki S 2007 Y Y N Y Y N N Y Y Y Y 7
PEDro criteria: (1) eligibility criteria, (2) random allocation, (3) concealed
allocation, (4) baseline comparability, (5) participant blinding, (6) therapist
blinding, (7) assessor blinding, (8) >85 % follow-up, (9) intention-to-treat
analysis, (10) between-groups statistical comparison for at least one key
outcome, and (11) point estimates and variability measures for at least one
key outcome. A trial with a score of 6 or more was considered high quality.BMD in zone 5 (WMD= 0.564, 95 % CI: −0.855 ~ −1.983,
P = 0.436).
Six papers [12, 13, 15, 17, 19, 20] described the post-
operative BMD ratios at 12 months, and the same pro-
cedure of analysis was performed. The Forest plots also
indicated that the BMD of the bisphosphonates group
were significantly higher (P < 0.05, Table 5) than that of
the control group except zone 5 with no statistical differ-
ence (P = 0.696, Table 5).
The postoperative BMD ratios at 5 years after surgery
were calculated in two studies [7, 19], and fixed-effect
model was used in all zones as no heterogeneity was de-
tected. The results of meta-analysis showed that BMD of
the bisphosphonates group in zones 6 and 7 were signifi-
cantly higher (P < 0.05) than that of the control group,
while no statistical difference were found in the rest of
the zones (P > 0.05, Table 6).Serum bone alkaline phosphates
Two papers [17, 18] including 71 patients in the
bisphosphonates group and 69 patients in the control
group described the postoperative serum BAP at
3 months, fixed-effect model was used as heterogeneity
was not detected (P = 0.222, I2 = 33). The pooling result
showed the serum BAP in the bisphosphonates group
was significantly lower than that of the control group
Table 3 Comparison of postoperative BMD ratios at 3 months between each group
ROI BMD ratios in the
bisphosphonates group
BMD ratios in the control
group
WMD [95 % CI] P of chi-
square
I2 Selected model P for overall
effect
1 97.556 90.840 6.364 2.122 10.606 0 92 % Random-effect
model
0.003
2 96.275 93.488 2.479 1.886 3.072 0.564 0 % Fixed-effect
model
<0.001
3 97.041 95.413 1.309 0.824 1.794 0.673 0 % Fixed-effect
model
<0.001
4 100.207 98.036 2.349 0.505 4.193 0.003 78 % Random-effect
model
0.013
5 97.528 97.172 −0.619 −1.120 −0.119 0.138 46 % Fixed-effect
model
0.015
6 95.641 92.724 2.177 1.598 2.756 0.552 0 % Fixed-effect
model
<0.001
7 91.099 84.457 6.634 0.655 12.612 0.001 95 % Random-effect
model
0.030
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Fig. 3).
The serum BAP at 6 months after surgery was re-
ported in four [14, 15, 17, 18] of the ten studies, includ-
ing 116 patients in the bisphosphonates group and 107
patients in the control group, and the same procedure of
analysis was performed and random-effect model was
used (P = 0.049, I2 = 61.9 %). The results of meta-analysis
indicated that serum BAP of the bisphosphonates group
was significantly lower than that of the control group
(WMD = −5.874, 95 % CI: −8.332 ~ −3.416, P = 0.001,
Fig. 4).
Three studies [15, 17, 18] including 95 patients in the
bisphosphonates group and 86 patients in the control
group described the postoperative serum BAP at 12 months.
The Forest plots of fixed-effect model (P = 0.683, I2 = 0 %)
also indicated that serum BAP of the bisphosphonatesTable 4 Comparison of postoperative BMD ratios at 6 months betw
ROI BMD ratios in the
bisphosphonates group
BMD ratios in the control
group
WMD
1 98.035 89.227 8.422
2 97.881 93.224 4.142
3 97.974 95.954 1.930
4 99.810 98.305 1.357
5 99.638 98.188 0.564
6 96.283 92.148 3.863
7 87.788 79.417 8.371group was significantly lower than that of the control group
(WMD= −3.395, 95 % CI: −6.171 ~ −0.619, P = 0.017,
Fig. 5).
Urinary type I collagen N-telopeptide
The urinary NTX at 6 months after surgery was re-
ported in two [14, 15] of the ten studies, including 45
patients in the bisphosphonates group and 38 patients
in the control group, and random-effect model was
used (P = 0.049, I2 = 61.9 %). The pooling result indi-
cated that urinary NTX of the bisphosphonates group
was significantly lower than that of the control group
(WMD = −22.929, 95 % CI: −39.098 ~ −6.760, P = 0.005,
Fig. 6).
Yamasaki et al. [14] reported that the urinary NTX in
the bisphosphonates group at 12 months after surgery
was lower than that of the control group.een each group
[95 % CI] P of chi-
square
I2 Selected model P for overall
effect
4.313 12.531 0.001 88 % Random-effect
model
<0.001
0.611 7.672 0.001 85 % Random-effect
model
0.021
0.668 3.193 0.041 52 % Random-effect
model
0.003
0.188 2.525 0.039 53 % Random-effect
model
0.023
−0.855 1.983 0.015 59 % Random-effect
model
0.436
1.291 6.435 0.001 80 % Random-effect
model
0.003
4.239 12.503 0.001 86 % Random-effect
model
<0.001
Table 5 Comparison of postoperative BMD ratios at 12 months between each group
ROI BMD ratios in bisphosphonates
group
BMD ratios in control
group
WMD [95 % CI] P of chi-
square
I2 Selected model P for overall
effect
1 96.005 87.601 6.819 3.816 9.821 0.009 67 % Random-effect
model
<0.001
2 99.032 92.431 6.250 5.314 7.186 0.386 8 % Fixed-effect model <0.001
3 99.786 97.172 2.822 0.615 5.029 0.001 86 % Random-effect
model
0.012
4 101.002 98.085 2.540 0.948 4.132 0.002 73 % Random-effect
model
0.002
5 101.189 100.601 −0.303 −1.823 1.218 0.074 50 % Fixed-effect model 0.696
6 97.458 91.817 5.220 3.262 7.178 0.018 63 % Random-effect
model
<0.001
7 85.797 77.128 8.153 5.130 11.175 0.002 73 % Random-effect
model
<0.001
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THA is an effective treatment for end-stage hip disease,
but the aseptic loosening of implants and the peripros-
thetic fracture secondary to periprosthetic bone loss re-
main an unresolved problem. Three mechanisms are
thought to contribute to femoral periprosthetic bone re-
sorption [21]. (1) The intraoperative mechanical, ther-
mal, and chemical damage cause necrosis in bone stock
of variable size. It might take approximately 3 months to
heal; (2) Delayed bone resorption process called ‘stress
shielding’ occurs in proximal regions of the femur, which
is related to the biomechanical characteristics of the
bone-implant structure and the difference in stiffness of
the prosthesis compared to the surrounding bone. Stress
shielding tends to stabilize by 1 year postoperatively.
(3) The inflammatory response caused by the detritus
produced by the wear and tear of prosthesis is another
reason for osteolysis, which mainly happens 5 years
after surgery. If an ideal drug suppressing the bone re-
sorption after THA was found, the service life ofTable 6 Comparison of postoperative BMD ratios at 5 years betwee
ROI BMD ratios in bisphosphonates
group
BMD ratios in control
group
WMD
1 98.301 93.225 3.113
2 95.222 93.382 −0.391
3 95.092 96.161 −2.885
4 95.685 96.943 −2.756
5 95.570 96.829 −1.618
6 98.976 92.007 7.002
7 79.444 69.561 9.664prosthesis would be much prolonged by maintaining
BMD around it [21]. The antiresorptive effect of bis-
phosphonate is cell mediated, mainly by direct inhibi-
tory effect on osteoclastic recruitment [18, 21, 22]. For
patients after THA, the administration of bisphospho-
nates may decrease the risk of future hip fractures, re-
duce the chances of subsidence of the stem, lower the
risk of revision, and prolong the survival time of pros-
thesis; however, some studies still doubt its long-term
efficacy [13, 23-25].
The results of our meta-analysis indicated that the
periprosthetic BMD in the bisphosphonate group was
higher than that of the control group in most areas at
3, 6, and 12 months postoperatively. This effect
seemed to persist in the main load-bearing areas of
zones 6 and 7 at 5 years postoperatively. These results
suggest that bisphosphonates decrease early femoral
periprosthetic bone resorption after primary cement-
less THA and their efficacy are long-standing in the
main load-bearing zones. Then, we discussed then each group
[95 % CI] P of chi-
square
I2 Selected model P for overall
effect
−7.234 13.461 0.364 0 % Fixed-effect
model
0.555
−6.359 5.578 0.387 0 % Fixed-effect
model
0.898
−6.893 1.123 0.508 0 % Fixed-effect
model
0.158
−6.559 1.047 0.640 0 % Fixed-effect
model
0.155
−5.633 2.398 0.750 0 % Fixed-effect
model
0.430
0.004 14.001 0.925 0 % Fixed-effect
model
0.050
1.754 17.575 0.852 0 % Fixed-effect
model
0.017
Fig. 3 Comparison of serum BAP between the bisphosphonate and control group at 3 months
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mechanical characteristic in the proximal-medial area
of the femur after THA. The normal mechanical load-
ing in proximal femur starts in zone 7, then goes down
to the cortical bone of zone 6. After turning to zone 3,
the mechanical loading will continue downward. The
cortical bone of zones 1 and 2 also shares part of the
loading. After THA, the stress shielding will cause sig-
nificant decrease in load bearing in zones 1, 2, 3, 6,
and 7. However, the load bearing in zone 5 does not
change apparently [26, 27]. In our study, the pooling
results at 3 months after surgery indicated the BMD of
the bisphosphonates group was all significantly higher
than that of the control group except zone 5. The rea-
son for this phenomenon might be that the bone re-
sorption due to stress shielding was significantly
suppressed by bisphosphonates in most zones; how-
ever, stress shielding is not apparent in zone 5, whichFig. 4 Comparison of serum BAP between the bisphosphonate and controlimits the antiresorptive efficacy of bisphosphonates
[26, 27]. As the accumulation of bone formation, no
difference was detected in zone 5 at 6 and 12 month
after surgery. After 3 months, the reconstruction of
the intraoperative bone damage has finished and the
bone resorption induced by stress shielding becomes
the leading effect [12, 13, 19, 28], so the BMD in the
bisphosphonates group were found to be higher than
that of the control group except zone 5. At the fifth
postoperative year, by pooling the results of the exist-
ing studies, we found that the BMD of the main load-
bearing zones 6 and 7 in the bisphosphonates group
was still higher than that of the control group, which
suggests that the efficacy of limited course of bispho-
sphonates in the existing studies are long-standing in
the main load-bearing zones.
The results of our meta-analysis showed that the
serum BAP and urinary NTX were suppressed byl group at 6 months
Fig. 5 Comparison of serum BAP between the bisphosphonate and control group at 12 months
Zhao et al. Journal of Orthopaedic Surgery and Research  (2015) 10:65 Page 8 of 9bisphosphonates in postoperative 1 year, which also
proves the antiresorptive efficacy of bisphosphonates
from metabolic level.
Only one of our included studies had a course of bispho-
sphonates lasting for 1 year, the rest were all less than
6 months, and all follow-up were less than 6 years. Eber-
hardt et al. [29] reported that postoperative continuous and
high-dose bisphosphonate treatment is potent in accelerat-
ing osseointegration of the prosthesis, which may prevent
wear debris from migration by sealing the implant-bone
interface. However, the efficacy of bisphosphonates on this
phenomenon needs further research as the limited course
of treatment and follow-up in our study. The current
studies suggest that the timing of the administration
of bisphosphonate may be related to its efficacy [6, 16,
18]; a long-term administration of bisphosphonate is
well tolerated and can increase BMD remarkably [30].
Considering that bone loss around the prosthesis of
THA is suspected to be progressive and faster than
that due to normal aging, Skoldenberg et al. [13] sug-
gested that the duration of bisphosphonate treatment
should be lifelong to achieve a reduced risk of revisionFig. 6 Comparison of urinary NTX between the bisphosphonate and contrand an improved quality of life; however, this hypoth-
esis needs further research.
The limitations of our study include the following.
(1) The BMD results of meta-analysis of some ROI ap-
peared heterogeneous, and sensitivity analysis and
subgroup analyses failed to eliminate the heterogen-
eity. As those results of meta-analysis had clinical
agreement, we included those studies and conducted
the meta-analysis by random-effect model for the rea-
son that those studies were of high quality, which may
slightly influence the reliability of the meta-analysis.
(2) The included studies did not have sufficient dur-
ation of bisphosphonate treatment and follow-up, and
they also lacked evaluating indexes like functional
scores and the rate of revision, so we could not evalu-
ate the efficacy of postoperative bisphosphonate treat-
ment comprehensively.
Conclusion
Bisphosphonates seem to decrease early femoral peri-
prosthetic bone resorption after primary cementless
THA, their efficacy are long-standing in the mainol group at 6 months
Zhao et al. Journal of Orthopaedic Surgery and Research  (2015) 10:65 Page 9 of 9load-bearing zones. Considering the conclusions of other
researches and the fact that most of our included studies
just had a course of bisphosphonates treatment for less
than 6 months, the long-term effects should be evaluated
by new RCTs, which should be performed with a longer
duration of bisphosphonates administration and follow-up
to clarify the best dosage and duration of bisphosphonates
treatment.
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